keyword
https://read.qxmd.com/read/38512645/utilization-of-anti-obesity-medications-after-bariatric-surgery-analysis-of-a-large-national-database
#21
JOURNAL ARTICLE
Stephen A Firkins, Vibhu Chittajallu, Bailey Flora, Heesoo Yoo, Roberto Simons-Linares
PURPOSE: A significant proportion of patients experience insufficient weight loss or weight regain after bariatric surgery. There is a paucity of literature describing anti-obesity medication (AOM) use following bariatric surgery. We sought to identify prevalence and trends of AOM use following bariatric surgery. MATERIALS AND METHODS: We utilized the IBM Explorys® database to identify all adults with prior bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)...
March 21, 2024: Obesity Surgery
https://read.qxmd.com/read/38511597/physiological-and-psychological-determinants-of-long-term-diet-induced-type-2-diabetes-t2dm-remission-a-narrative-review
#22
REVIEW
Ayse Nur Aksoy, Julie Abayomi, Nicola Relph, Thomas Butler
Type 2 diabetes mellitus (T2DM) is a highly prevalent metabolic disease, causing a heavy burden on healthcare systems worldwide, with related complications and anti-diabetes drug prescriptions. Recently, it was demonstrated that T2DM can be put into remission via significant weight loss using low-carbohydrate diets (LCDs) and very low-energy diets (VLEDs) in individuals with overweight and obesity. Clinical trials demonstrated remission rates of 25-77%, and metabolic improvements such as improved blood lipid profile and blood pressure were observed...
March 21, 2024: Obesity Reviews
https://read.qxmd.com/read/38504118/dipeptidyl-peptidase-4-inhibitor-and-sodium-glucose-cotransporter-2-inhibitor-additively-ameliorate-hepatic-steatosis-through-different-mechanisms-of-action-in-high-fat-diet-fed-mice
#23
JOURNAL ARTICLE
Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
AIM: Dipeptidyl peptidase-4 (DPP-4) inhibitors suppress the inactivation of incretin hormones and lower blood glucose levels by inhibiting DPP-4 function. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in an insulin-independent manner by inhibiting renal reabsorption of glucose. DPP-4 and SGLT2 inhibitors each have the potential to improve hepatic steatosis; however, their combined effects remain unclear. In this study, we examined the effects of the combination of these drugs on hepatic steatosis using high-fat diet-fed mice...
March 19, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38490492/the-effect-of-subcutaneous-lixisenatide-on-weight-loss-in-patients-with-type-2-diabetes-mellitus-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#24
REVIEW
Lei Sheng, Meixian Deng, Xin Li, Huan Wan, Changjiang Lei, Kousalya Prabahar, Benjamin Hernández-Wolters, Hamed Kord-Varkaneh
BACKGROUND: The impacts of subcutaneous Lixisenatide on body weight in patients with type 2 DM, remain inadequately understood; consequently, this systematic review and meta-regression analysis of randomized controlled trials (RCTs) was conducted to evaluate the influence of subcutaneous Lixisenatide administration on BW and BMI values in individuals with Type 2 diabetes. METHODS: A comprehensive literature search was conducted across four databases, spanning from their inception to February 2023...
March 14, 2024: Diabetes Research and Clinical Practice
https://read.qxmd.com/read/38490125/relationship-between-adiponectin-and-muscle-mass-in-patients-with-metabolic-syndrome-and-obesity
#25
JOURNAL ARTICLE
Daniel de Luis, David Primo, Olatz Izaola, Juan José Lopez Gomez
BACKGROUND: Adiponectin is one of the most important adipokines in human beings. Obesity and sarcopenia are associated with a low-level chronic inflammatory status, and adiponectin plays an anti-inflammatory role. AIMS: The objective of the current work was to study the association between muscle mass, determined via bioelectrical impedance (BIA), and circulating adiponectin levels among obese patients with metabolic syndrome who are older than 60 years of age...
April 2024: Journal of Diabetes and its Complications
https://read.qxmd.com/read/38472647/animal-studies-on-glucagon-like-peptide-1-receptor-agonists-and-related-polyagonists-in-nonalcoholic-fatty-liver-disease
#26
REVIEW
Chara Tsiampali, Ilias D Vachliotis, Antonis Goulas, Stergios A Polyzos
Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic liver disease closely associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM), but without licensed pharmacological treatment to date. As glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are approved anti-diabetic and anti-obesity medications, they were also considered a potential therapeutic option for NAFLD. Preclinical studies suggest that GLP-1RAs have a beneficial effect on major NAFLD histological outcomes, i...
March 12, 2024: Hormones: International Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/38469598/the-association-between-previous-use-of-anti-obesity-medication-and-semaglutide-weight-loss-outcomes
#27
JOURNAL ARTICLE
Wissam Ghusn, Sima Fansa, Diego Anazco, Elif Tama, Lizeth Cifuentes, Khushboo Gala, Alan De La Rosa, Daniel Sacoto, Alejandro Campos, Fauzi Feris, Daniela Hurtado, Andres Acosta
AIMS: To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti-obesity medication (AOM) compared to those who were AOM-naïve. MATERIALS AND METHODS: We performed a retrospective study in patients with overweight or obesity taking semaglutide for weight loss for a duration of 3 to 12 months. Our primary endpoint was assessment of percentage of total body weight loss (TBWL) in patients who started semaglutide as their first AOM (AOM-naïve) compared to those who started semaglutide and had previously taken another AOM (non-AOM-naïve)...
March 12, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38469405/intestinal-mucosal-barrier-a-potential-target-for-traditional-chinese-medicine-in-the-treatment-of-cardiovascular-diseases
#28
REVIEW
Jiahui Liu, Xiunan Wei, Tong Wang, Miaomiao Zhang, Ying Gao, Yan Cheng, Lili Chi
Cardiovascular disease (CVD) is a serious public health problem, and among non-communicable diseases, CVD is now the leading cause of mortality and morbidity worldwide. CVD involves multiple organs throughout the body, especially the intestinal tract is the first to be involved. The impairment of the intestinal mucosal barrier is considered a significant pathological alteration in CVD and also contributes to the accelerated progression of the disease, thereby offering novel insights for CVD prevention and treatment...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38468148/the-impact-of-metformin-on-weight-and-metabolic-parameters-in-patients-with-obesity-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#29
JOURNAL ARTICLE
Rachelle Haber, Fatima Zarzour, Malak Ghezzawi, Natalie Saadeh, Dania S Bacha, Lama Al Jebbawi, Marlene Chakhtoura, Christos S Mantzoros
There are conflicting data on the weight-reducing potential of metformin (MTF) in nondiabetic patients with obesity. The purpose of this systematic review and meta-analysis was to evaluate the effect of MTF on weight and cardiometabolic parameters in adults with overweight/obesity with or without nonalcoholic fatty liver disease (NAFLD) (CRD42018085512). We included randomized controlled trials (RCTs) in adults without diabetes mellitus, with mean body mass index (BMI) ≥ 25 kg/m2 , with or without NAFLD, comparing MTF to placebo/control, lifestyle modification (LSM) or a US Food and Drug Administration-approved anti-obesity drug, reporting on weight or metabolic parameters, and extending over at least 3 months...
March 11, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38449298/neurocysticercosis-presenting-as-migraine-in-the-united-states
#30
JOURNAL ARTICLE
Eamonn Byrnes, Brian Shaw, Ryan Shaw, Mario Madruga, Stephen J Carlan
BACKGROUND Cysticercosis is a condition caused by infection with the larval form of Taenia solium, a pork tapeworm that uses pigs as an intermediate host. Humans become infected when they ingest water or food contaminated with tapeworm cysts. Cysticercosis is increasing in frequency in developed countries due to increased access to travel. Neurocysticercosis occurs when Taenia solium cysts embed within the nervous system. The clinical presentation of neurocysticercosis ranges from asymptomatic to life-threatening, largely depending on the brain parenchymal involvement...
March 7, 2024: American Journal of Case Reports
https://read.qxmd.com/read/38436917/metabolic-recovery-with-the-persistence-of-proinflammatory-leucocyte-dysfunction-after-bariatric-intervention-for-obesity
#31
JOURNAL ARTICLE
Arturo Cérbulo-Vázquez, Libier Cabrera-Rivera, Ismael Mancilla-Herrera, Denisse Castro-Eguiluz, Francisco J Sánchez-García, Eduardo A Ferat-Osorio, Lourdes A Arriaga-Pizano
PURPOSE: A suitable option for severe obesity treatment is a surgical approach. After surgery, metabolic markers and weight frequently return to adequate values; however, concerning systemic inflammatory mediators, the results are inconsistent. Furthermore, it has been suggested that leucocyte function may be affected even after weight normalization. This study aimed to determine if the surgical treatment of obesity influences the production of cytokines by LPS-stimulated as a function of leucocytes...
March 4, 2024: Obesity Surgery
https://read.qxmd.com/read/38430483/association-between-metformin-treatment-and-coronary-artery-inflammation-based-on-pericoronary-adipose-tissue-attenuation-in-type-2-diabetes-mellitus-patients
#32
JOURNAL ARTICLE
Yuankang Liu, Yue Dong, Xiang Wang, Xiangyang Xu
Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM) patients. The role of metformin in reducing cardiovascular events is well-established, but its effect on coronary artery inflammation in T2DM patients is still unclear. In this study, we evaluated 547 T2DM patients who underwent coronary computed tomography angiography (CCTA) at Wuhan Central Hospital. Using propensity score matching, we compared the attenuation of pericoronary adipose tissue (PCAT), an imaging marker of coronary artery inflammation, between patients treated with and without metformin...
March 2, 2024: Journal of Clinical Hypertension
https://read.qxmd.com/read/38428704/biological-activities-molecular-mechanisms-and-clinical-application-of-naringin-in-metabolic-syndrome
#33
JOURNAL ARTICLE
Jie Chen, Xiang Qin, Mengyao Chen, Tianzhu Chen, Zheng Chen, Beihui He
Metabolic syndrome has become major health problems in recent decades, and natural compounds receive considerable attention in the management of metabolic syndrome. Among them, naringin is abundant in citrus fruits and tomatoes. Many studies have investigated the therapeutic effects of naringin in metabolic syndrome. This review discusses in vitro and in vivo studies on naringin and implications for clinical trials on metabolic syndrome such as diabetes mellitus, obesity, nonalcoholic fatty liver disease, dyslipidemia, and hypertension over the past decades, overviews the molecular mechanisms by which naringin targets metabolic syndrome, and analyzes possible correlations between the different mechanisms...
February 29, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38426245/turning-fat-into-muscle-can-this-be-an-alternative-to-anti-obesity-drugs-such-as-semaglutide
#34
JOURNAL ARTICLE
Henning Wackerhage, Arne Hinrichs, Eckhard Wolf, Martin Hrabě de Angelis
No abstract text is available yet for this article.
March 1, 2024: Journal of Physiology
https://read.qxmd.com/read/38424145/predictors-of-microvascular-complications-in-patients-with-type-2-diabetes-mellitus-at-regional-referral-hospitals-in-the-central-zone-tanzania-a-cross-sectional-study
#35
JOURNAL ARTICLE
Wilfred B Shillah, James J Yahaya, Emmanuel D Morgan, Deogratius Bintabara
Microvascular complications encompass a group of diseases which result from long-standing chronic effect of diabetes mellitus (DM). We aimed to determine the prevalence of microvascular complications and associated risk factors among patients with type 2 diabetes mellitus (T2DM). A cross-sectional analytical hospital-based study was conducted at Singida and Dodoma regional referral hospitals in Tanzania from December 2021 to September 2022. A total of 422 patients with T2DM were included in the analysis by determining the prevalence of microvascular complications and their predictors using multivariable logistic regression analysis...
February 29, 2024: Scientific Reports
https://read.qxmd.com/read/38419410/pharmacological-treatment-of-obesity-in-adults-in-norway-2004-2022
#36
JOURNAL ARTICLE
Paz Lopez-Doriga Ruiz, Øystein Karlstad, Kjersti Nøkleby, Kristina Slåtsve, Hanne L Gulseth, Haakon E Meyer, Kari Anne Sveen, Elisabeth Qvigstad, Kari Furu
AIMS: To describe trends in the use of anti-obesity drugs in Norway during the period 2004-2022. MATERIALS AND METHODS: We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18-79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18-29 years and 10-year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti-obesity drug and on the cost of the anti-obesity drugs since 2017...
February 28, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38419375/bacoside-a-repressed-the-differentiation-and-lipid-accumulation-of-3t3-l1-preadipocytes-by-modulating-the-expression-of-adipogenic-genes
#37
JOURNAL ARTICLE
Thiyagarajan Ramesh, Mohammad Shahid
Obesity is one of the more complicated diseases, it can induce numerous life-threatening diseases mainly diabetes mellitus, cardiovascular disease, hypertension, and certain cancers. In this study, we assessed the efficacy of bacoside-A (a dammarane-type triterpenoid saponin derived from the plant Bacopa monniera Linn.) on the adipogenesis of 3T3-L1 preadipocytes. Results of this study illustrated that bacoside-A decreased the differentiation of 3T3-L1 cell, as evidenced by diminution of lipid droplets, which contains triglycerides and other lipids...
February 28, 2024: Biotechnology and Applied Biochemistry
https://read.qxmd.com/read/38415495/the-natural-products-as-novel-anti-obesity-agents-mechanisms-based-on-adipose-tissue
#38
JOURNAL ARTICLE
Lei Cao, Chunwei Wu, Miao Liu, Wenlong Zhang, Hailong Chen, Ruolin Wang, Ze He
Obesity presently stands as a formidable global public health concern, exerting a profound impact on human life and well-being. Despite the plethora of pharmacological interventions targeting obesity, their extensive use in clinical settings is hindered by the emergence of numerous adverse reactions during drug interventions. Naturally occurring compounds or extracts found in traditional Chinese medicine, fruits, and vegetables, possessing various attributes, such as metabolic modulation, thermogenic induction, appetite alteration, and inhibition of lipase activity and fat synthesis, have positioned themselves as potential anti-obesity pharmaceutical candidates...
February 23, 2024: Current Diabetes Reviews
https://read.qxmd.com/read/38409502/associations-of-a-proinflammatory-diet-habitual-salt-intake-and-the-onset-of-type-2-diabetes-a-prospective-cohort-study-from-the-uk-biobank
#39
JOURNAL ARTICLE
Wenqi Shen, Lingli Cai, Bin Wang, Jiang Li, Ying Sun, Yi Chen, Fangzhen Xia, Ningjian Wang, Yingli Lu
AIM: To explore the relationship between proinflammatory diet, habitual salt intake and the onset of type 2 diabetes. METHODS: This prospective study was conducted among 171 094 UK Biobank participants who completed at least one 24-h dietary questionnaire and were free of diabetes at baseline. Participants were followed up until 1 March 2023 for type 2 diabetes incidence, with diagnosis information obtained from linked medical records. An Energy-adjusted Diet Inflammatory Index (E-DII) was calculated based on 28 food parameters...
February 26, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38409061/high-dietary-inflammatory-index-associates-with-inflammatory-proteins-in-plasma
#40
JOURNAL ARTICLE
Elisa Mattavelli, Elisa Piperni, Francesco Asnicar, Laura Redaelli, Liliana Grigore, Fabio Pellegatta, Amir Nabinejad, Sabrina Tamburini, Nicola Segata, Alberico Luigi Catapano, Andrea Baragetti
BACKGROUND AND AIM: Unhealthy dietary habits and highly caloric foods induce metabolic alterations and promote the development of the inflammatory consequences of obesity, insulin resistance, diabetes and cardiovascular diseases. Describing an inflammatory effect of diet is difficult to pursue, owing lacks of standardized quali-quantitative dietary assessments. The Dietary Inflammatory Index (DII) has been proposed as an estimator of the pro- or anti-inflammatory effect of nutrients and higher DII values, which indicate an increased intake of nutrients with pro-inflammatory effects, relate to an increased risk of metabolic and cardiovascular diseases and we here assessed whether they reflect biologically relevant plasmatic variations of inflammatory proteins...
February 26, 2024: Diabetology & Metabolic Syndrome
keyword
keyword
78651
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.